Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
While activating mutations of NOTCH1 are observed in most T-ALL cases, these mutations alone are not sufficient to drive the full development of T-ALL.
|
31822496 |
2020 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, it is known that NOTCH1 antagonizes IKZF1 in T-ALL.
|
30578688 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
To directly explore whether IL-7R targeting may be therapeutically efficient against T-ALL relapse, we focused on a known Notch1-induced T-ALL model, because a majority of T-ALL patients harbor activating mutations in NOTCH1, which is a transcriptional regulator of IL-7R expression.
|
31530562 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Since more than 60% of T-ALL cases bear oncogenic NOTCH1 mutations, small molecule inhibitors of NOTCH1 signalling; γ-secretase inhibitors (GSI), are being actively investigated for the treatment of T-ALL.
|
30967635 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Testing of Notch1-targeting therapeutic antibodies demonstrated T-ALL sensitivity to different classes of Notch1 blockers based on Notch1 mutational status.
|
31399482 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Similar to <i>Bcor</i>-deficient mice, <i>Kdm2b</i>-deficient mice developed lethal T-ALL mostly in a NOTCH1-dependent manner.
|
31471323 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
To investigate the prognostic value of NOTCH1 associated with lncRNA in T cell acute lymphoblastic leukemia 1 (NALT1) in GC and the mechanism of its involvement in GC invasion and metastasis.
|
31802831 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Despite the limitations of having a small sample size and a non-minimal residual disease-based protocol, our results suggest that the presence of NOTCH1 mutations might contribute to the disease relapse of T-ALL.
|
30387229 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Treatment of T-ALL cell lines with the selective PSEN1 inhibitor MRK-560 effectively decreased mutant NOTCH1 processing and led to cell cycle arrest.
|
31142678 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Consistent with a leukemia-initiating tumor suppressor role, inactivation of <i>Phf6</i> in hematopoietic progenitors lowers the threshold for the development of NOTCH1-induced T-ALL.
|
30567843 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We previously demonstrated that the Notch1-specific neutralizing antibody OMP52M51 prolongs survival in T-cell acute lymphoblastic leukemia patient-derived xenografts bearing NOTCH1/FBW7 mutations.
|
31467126 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The identification of activating mutations in NOTCH1 in 50% of T cell acute lymphoblastic leukemia has generated interest in elucidating how these mutations contribute to oncogenic transformation and in targeting the pathway.
|
30643281 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Then, cells from each population were retrovirally transduced to initiate MLL-AF9 acute myelogenous leukemia (AML) and the intracellular domain of NOTCH-1 T-cell acute lymphoblastic leukemia (T-ALL).
|
30733302 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We used the Notch1-driven T-ALL model as a benchmark comparison and AMD3100 for CXCR4 antagonism experiments.
|
30422351 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
<i>USP7</i> is highly expressed in T-ALL and is transcriptionally regulated by NOTCH1.
|
30224337 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Overall our findings indicate JMJD3 and p300 as general Notch1 and Notch3 signaling co-activators in T-ALL and suggest further investigation on the potential therapeutic anti-leukemic efficacy of their enzymatic inhibition in Notch/c-Myc axis-related cancers and diseases.
|
31001470 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The nuclear expression of NOTCH1 protein was detected in 25% and 5% of cases of T-ALL/LBL and CLL/SLL, respectively, whereas cytoplasmic expression was detected in 33.3% and 15% cases, respectively.
|
30718223 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
miR-200b promotes cell proliferation and invasion in t-cell acute Lymphoblastic leukemia through NOTCH1.
|
30574752 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Here, using the TEL-JAK2 transgenic (TJ2-Tg) mouse model of T-ALL/LBL, which is driven by constitutive JAK/STAT signaling and characterized by the acquisition of Notch1 mutations, we sought to identify stromal cell alterations associated with thymic leukemogenesis.
|
30256907 |
2018 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In an established model of Notch1-driven T-cell acute lymphoblastic leukemia (T-ALL), MBD2 ablation impeded malignant progression and maintenance by attenuating the Wnt signaling pathway.
|
29330145 |
2018 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
USP7 deubiquitinates and stabilizes NOTCH1 in T-cell acute lymphoblastic leukemia.
|
30370059 |
2018 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Notably, CD44 is shown to support crucial BM niche interactions necessary for LIC activity of human T-ALL xenografts and disease progression, highlighting the importance of the NOTCH1/CD44 axis in T-ALL pathogenesis.
|
29781813 |
2018 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
NOTCH1/FBXW7 mutations trigger oncogenic NOTCH1 signaling and its downstream target genes play crucial roles in the molecular pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL).
|
29200162 |
2018 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Deletion of STIM1 and STIM2 in leukemic cells abolishes SOCE and significantly prolongs the survival of mice in a NOTCH1-dependent model of T-ALL.
|
30208327 |
2018 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The SERCA (sarco-endoplasmic reticulum Ca<sup>2+</sup> ATPase) inhibitor thapsigargin inhibits mutant NOTCH1 receptors compared with wild type in T cell acute lymphoblastic leukemia (T-ALL), but its administration is predicted to be toxic in humans.
|
29158376 |
2018 |